OraSure delivered Q4 revenue above consensus, with molecular diagnostics sales leading the outperformance. The company noted growing demand for its rapid infectious disease assays in clinical and point-of-care settings.

Management emphasized progress in its digital and home testing division, citing increased order volume and new partnerships to distribute at-home health tests. The Everlywell collaboration was highlighted as a key driver for consumer adoption.

Although specific margin figures were not disclosed, executives reiterated a commitment to improving operating leverage as volume scales. No formal update to full-year guidance was issued, with the company maintaining prior targets for revenue growth and profitability.